Ticker

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst expectations for revenue and adjusted earnings, while...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) told investors that revenue growth accelerated in its second half and has guided for a further step-up in the current year as Grassmuno enters its first full peak treatment season. Second-half revenue is expected to reach £23.6 million, up more than 12% on a reported basis from £21 million a year earlier.

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has appointed former HSBC banker Helge Weiner-Trapness as executive chairman as the biotechnology...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF, FRA:HHU) has appointed former HSBC banker Helge Weiner-Trapness as executive chairman as the biotechnology group explores a potential dual primary listing in Hong Kong. Weiner-Trapness, who joined the group as chief strategy officer and an executive director in January 2026, brings more than 30 years of investment banking experience in the US and Asia.